摘要
目的了解冠心病患者择期冠状动脉介入治疗(percutaneous coronary intervention,PCI)术前服用大剂量阿托伐他汀对血清高敏C反应蛋白(high-sensitivity C-reactive protein,hs-CRP)及肾功能的影响。方法选择冠心病择期冠状动脉造影检查需要PCI治疗的患者173例,随机分为大剂量阿托伐他汀组(AS组,n=76)和常规治疗组(C组,n=97),治疗7天后行PCI术。术前和术后检测血清hs-CRP、血清肌酐(serum creatinine,SCr),计算肾小球滤过率(glo-merular filtration rate,GFR)。结果两组患者术前24h血hs-CRP水平,低于入院时(t=2.413和2.309,P<0.05)和术后48h(t=2.087和2.368,P<0.05);AS组PCI术前24h和术后48h血清hs-CRP均低于C组(t=2.007和2.275,P<0.05)。两组PCI术后SCr较术前升高(t=2.464和2.392,P<0.05),GFR较术前降低(t=2.496和2.573,P<0.05);术后AS组SCr低于C组(t=2.337,P<0.05),GFR高于C组(t=2.145,P<0.05)。AS组对比剂肾病(contrast-induced nephropathy,CIN)发生率低于C组(6.58%vs16.49%,χ2=3.93,P<0.05)。结论冠心病择期PCI患者术前服用大剂量阿托伐他汀对CIN可能有良好的预防作用,机制可能与显著抑制炎症反应有关。
Objective To investigate the effect of high-dose atorvastatin on serum high-sensitivity C-reactive protein(hs-CRP) and renal function in patients with coronary heart disease(CHD) undergoing elective percutaneous coronary intervention(PCI).Methods Among 237 CHD patients undergoing elective coronary angiography,173 cases undergoing PCI were randomly divided into high-dose atorvastatin group(group AS,n=76) and conventional treatment group(group C,n=97).They were treated using drugs for 7 days before PCI.Preoperative and postoperative serum hs-CRP,serum creatinine(SCr) were detected and glomerular filtration rate(GFR) was calculated.Results Serum hs-CRP at 24 hours pre-PCI was lower than the level at admission(t=2.413,2.309,P〈0.05) and at 48 hours post-PCI(t=2.087,2.368,P〈0.05) in the two groups.Serum hs-CRP at 24 hours pre-PCI and 48 hours post-PCI were lower in group AS than in group C(t=2.007,2.275,P〈0.05).SCr levels were increased and GFR levels were decreased in two groups after PCI(t=2.464,2.392,P〈0.05).SCr level was lower(t=2.337,P〈0.05) and GFR level was higher(t=2.145,P〈0.05) in group AS than group C.The incidence of contrast-induced nephropathy(CIN) was lower in group AS than that in group C(6.58% vs 16.49%,χ^2=3.93,P〈0.05).Conclusion High-dose atorvastatin may be effective in protecting CHD patients undergoing PCI from CIN.The underlying mechanism may relate with the significant inhibition on the inflammatory response.
出处
《华南国防医学杂志》
CAS
2010年第6期448-451,共4页
Military Medical Journal of South China
关键词
对比剂肾病
阿托伐他汀
冠心病
冠状动脉介入治疗
Contrast-induced nephropathy
Atorvastatin
Coronary heart disease
Percutaneous coronary intervention